Loading institutional data...
Loading institutional data...
Strong institutional distribution: ownership decreased -6.29% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $1.36 today, the market must believe free cash flow compounds 3.5%/yr for a decade (off $5M normalized FCF).
2-stage DCF · 0.13B shares · net debt -$94M
mean -283.8% · volatility σ 351% · implied rate exceeded in 0/3 yrs
Central path = implied 3.5%/yr growth; shaded band = ±1σ (351%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $564.2M 100.0% | $482.0M 100.0% | $433.1M 100.0% | $450.9M 100.0% | $467.4M 100.0% | $338.3M 100.0% | $261.0M 100.0% | $193.4M 100.0% | $198.5M 100.0% | $138.7M 100.0% |
| Cost of Revenue | — | $115.7M 24.0% | $106.5M 24.6% | $105.0M 23.3% | $114.2M 24.4% | $87.3M 25.8% | $75.9M 29.1% | $68.8M 35.6% | $61.2M 30.8% | $48.2M 34.7% |
| Gross Profit | — | $366.3M 76.0% | $326.7M 75.4% | $345.9M 76.7% | $353.2M 75.6% | $251.0M 74.2% | $185.0M 70.9% | $124.6M 64.4% | $137.3M 69.2% | $90.5M 65.3% |
| Research & Development | $44.5M 7.9% | $50.3M 10.4% | $44.4M 10.2% | $39.8M 8.8% | $30.7M 6.6% | $20.1M 5.9% | $14.8M 5.7% | $10.7M 5.6% | $9.1M 4.6% | $6.3M 4.5% |
| Selling, General & Admin | $326.2M 57.8% | $294.5M 61.1% | $269.8M 62.3% | $283.8M 62.9% | $250.2M 53.5% | $204.2M 60.4% | $200.1M 76.7% | $162.0M 83.7% | $133.7M 67.4% | $93.0M 67.1% |
| Total Operating Expenses | $519.5M 92.1% | $483.3M 100.3% | $420.6M 97.1% | $323.6M 71.8% | $280.9M 60.1% | $224.3M 66.3% | $214.9M 82.3% | $176.2M 91.1% | $142.8M 71.9% | $99.3M 71.6% |
| Operating Income | $44.7M 7.9% | -$1.3M -0.3% | $12.5M 2.9% | $22.3M 4.9% | $72.2M 15.5% | $26.7M 7.9% | -$29.9M -11.4% | -$51.6M -26.7% | -$5.5M -2.8% | -$8.8M -6.3% |
| Interest Expense | -$2.3M -0.4% | $1.5M 0.3% | $2.2M 0.5% | $2.0M 0.4% | $7.2M 1.5% | $11.3M 3.3% | $9.0M 3.4% | $10.8M 5.6% | $8.0M 4.0% | $5.6M 4.1% |
| Interest & Investment Income | — | — | — | — | — | — | — | $64K 0.0% | $129K 0.1% | $153K 0.1% |
| Other Income (Expense), net | $2.3M 0.4% | -$1.5M -0.3% | -$2.1M -0.5% | -$2.0M -0.4% | -$9.1M -2.0% | -$8.9M -2.6% | -$8.7M -3.3% | -$13.2M -6.8% | -$9.1M -4.6% | -$5.9M -4.3% |
| Pretax Income | $47.0M 8.3% | -$2.8M -0.6% | $10.4M 2.4% | $20.3M 4.5% | $63.1M 13.5% | $17.8M 5.3% | -$38.6M -14.8% | -$64.7M -33.5% | -$14.6M -7.3% | -$14.7M -10.6% |
| Income Tax Expense | $9.9M 1.8% | -$3.7M -0.8% | $5.4M 1.3% | $4.8M 1.1% | -$31.1M -6.7% | $530K 0.2% | $150K 0.1% | $84K 0.0% | -$7.0M -3.5% | $65K 0.0% |
| Net Income | $37.0M 6.6% | $900K 0.2% | $4.9M 1.1% | $15.5M 3.4% | $94.2M 20.2% | $17.2M 5.1% | -$38.7M -14.8% | -$64.8M -33.5% | -$8.4M -4.2% | -$17.0M -12.2% |
| Per Share | ||||||||||
| EPS (Basic) | $0.16 | $-0.01 | $0.04 | $0.12 | $0.73 | $0.16 | $-0.42 | $-0.94 | — | — |
| EPS (Diluted) | $0.15 | $-0.01 | $0.04 | $0.12 | $0.70 | $0.15 | $-0.42 | $-0.94 | — | — |
| Weighted Avg Shares (Basic) | 126.7M | 131.7M | 131.2M | 130.1M | 128.3M | 107.7M | 92.8M | 69.3M | — | — |
| Weighted Avg Shares (Diluted) | 130.2M | 131.7M | 132.7M | 132.4M | 133.7M | 111.4M | 92.8M | 69.3M | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
2/7 of the 9 checks — 2 couldn't be scored (see above), so the score is out of the 7 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$24M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 12%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $94M covers all $50M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2019-09-30 (10-Q).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 9-yr range · 0th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 9-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 35.6 | 29.1 | 25.8 | 24.4 | 23.3 | 24.6 | 24.0 | — |
| Gross Profit | 64.4 | 70.9 | 74.2 | 75.6 | 76.7 | 75.4 | 76.0 | — |
| R&D | 5.6 | 5.7 | 5.9 | 6.6 | 8.8 | 10.2 | 10.4 | 7.9 |
| SG&A | 83.7 | 76.7 | 60.4 | 53.5 | 62.9 | 62.3 | 61.1 | 57.8 |
| Operating Income | -26.7 | -11.4 | 7.9 | 15.5 | 4.9 | 2.9 | -0.3 | 7.9 |
| Income Tax | 0.0 | 0.1 | 0.2 | -6.7 | 1.1 | 1.3 | -0.8 | 1.8 |
| Net Income | -33.5 | -14.8 | 5.1 | 20.2 | 3.4 | 1.1 | 0.2 | 6.6 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ORGO: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ORGO | $173M | 9.1× | 1.3× | 0.3× | 17.0% | — | 6.6% | 12.3% | 12.3% | — | 121 |
Peers = companies sharing ORGO's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.